UY35393A - Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a - Google Patents
Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10aInfo
- Publication number
- UY35393A UY35393A UY0001035393A UY35393A UY35393A UY 35393 A UY35393 A UY 35393A UY 0001035393 A UY0001035393 A UY 0001035393A UY 35393 A UY35393 A UY 35393A UY 35393 A UY35393 A UY 35393A
- Authority
- UY
- Uruguay
- Prior art keywords
- disorders
- formula
- phosphodiesterase
- compounds
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
Abstract
Compuestos de la fórmula I, los N-óxidos, tautómeros, las prodrogas y las sales farmacéuticamente a ceptables de los mismos: En fórmula I la variable X1 es CH o N, X2 es O o S, y R1, R2, R3, R4 y Q son según se los definió en las reivindicaciones. Los compuestos de la fórmula I, los N-óxidos, tautómeros, las prodrogas y las sales farmacéuticame nte aceptables de los mismos son inhibidores de la fosfodiesterasa del tipo 10A. Por lo tanto, la invención también se refiere al uso de los compues tos de la fórmula I, los N-óxidos, tautómeros, las prodrogas y las sales farmacéuticamente aceptabl es de los mismos para la fabricación de un medica mento y que por lo tanto son apropiados para tratar o controlar trastornos médicos que se seleccion an entre: trastornos neurológicos y trastornos ps iquiátricos, para mejorar los síntomas asociados con dichos trastornos y para reducir el riesgo de dichos trastornos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779141P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35393A true UY35393A (es) | 2014-10-31 |
Family
ID=50241454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035393A UY35393A (es) | 2013-03-13 | 2014-03-12 | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9200005B2 (es) |
| EP (1) | EP2970328B1 (es) |
| JP (1) | JP2016510786A (es) |
| KR (1) | KR20150127724A (es) |
| CN (1) | CN105358561A (es) |
| AR (1) | AR095267A1 (es) |
| AU (1) | AU2014230825A1 (es) |
| BR (1) | BR112015022094A2 (es) |
| CA (1) | CA2902654A1 (es) |
| CL (1) | CL2015002545A1 (es) |
| CR (1) | CR20150496A (es) |
| DO (1) | DOP2015000214A (es) |
| HK (1) | HK1219273A1 (es) |
| IL (1) | IL240593A0 (es) |
| MX (1) | MX2015012389A (es) |
| PE (1) | PE20160040A1 (es) |
| PH (1) | PH12015501962A1 (es) |
| RU (1) | RU2015143536A (es) |
| SG (1) | SG11201507380PA (es) |
| TW (1) | TW201441230A (es) |
| UY (1) | UY35393A (es) |
| WO (1) | WO2014140086A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20161035A1 (es) | 2013-03-15 | 2016-11-13 | Global Blood Therapeutics Inc | Compuestos y usos de estos para la modulacion de la hemoglobina |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| JP6814730B2 (ja) | 2014-09-05 | 2021-01-20 | ジェネンテック， インコーポレイテッド | 治療用化合物およびその使用 |
| JP6767969B2 (ja) | 2014-09-05 | 2020-10-14 | ジェネンテック， インコーポレイテッド | がんの処置における使用のためのｐｃａｆおよびｇｃｎ５阻害剤としての式（ｉ）のフタラジン誘導体 |
| CN107406429B (zh) | 2015-01-09 | 2021-07-06 | 基因泰克公司 | 哒嗪酮衍生物及其在治疗癌症中的用途 |
| CA3067591A1 (en) * | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| CN115838364A (zh) * | 2022-12-20 | 2023-03-24 | 河南沁朋科技有限公司 | 一种3,3-双噻吩的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1284079A (zh) | 1997-12-05 | 2001-02-14 | 阿斯特拉曾尼卡英国有限公司 | 新化合物 |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| US20070032404A1 (en) | 2003-07-31 | 2007-02-08 | Bayer Pharmaceuticals Corporation | Methods for treating diabetes and related disorders using pde10a inhibitors |
| EP1755611A1 (en) | 2004-06-07 | 2007-02-28 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| MX2007002592A (es) | 2004-09-03 | 2007-10-10 | Memory Pharm Corp | Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos. |
| US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
| NL2000397C2 (nl) | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| WO2007082546A1 (en) | 2006-01-20 | 2007-07-26 | H. Lundbeck A/S | Use of tofisopam as a pde10a inhibitor |
| JP2009524637A (ja) | 2006-01-27 | 2009-07-02 | ファイザー・プロダクツ・インク | アミノフタラジン誘導体化合物 |
| CA2643983A1 (en) | 2006-02-21 | 2007-08-30 | Amgen, Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
| JP2009527560A (ja) | 2006-02-21 | 2009-07-30 | アムゲン インコーポレイティッド | ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体 |
| WO2007096743A1 (en) | 2006-02-23 | 2007-08-30 | Pfizer Products Inc. | Substituted quinazolines as pde10 inhibitors |
| WO2007100880A1 (en) | 2006-02-28 | 2007-09-07 | Amgen Inc. | Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors |
| US20070265258A1 (en) | 2006-03-06 | 2007-11-15 | Ruiping Liu | Quinazoline derivatives as phosphodiesterase 10 inhibitors |
| EP1996574A1 (en) | 2006-03-08 | 2008-12-03 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2654394A1 (en) | 2006-06-26 | 2008-01-03 | Pfizer Products Inc. | Tricyclic heteroaryl compounds as pde10 inhibitors |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| CN101495476A (zh) | 2006-07-10 | 2009-07-29 | H.隆德贝克有限公司 | 6,7-二烷氧基喹唑啉、6,7-二烷氧基酞嗪和6,7-二烷氧基异喹啉的(3-芳基-哌嗪-1-基)、(2-芳基-吗啉-4-基)和(2-芳基-硫代吗啉-4-基)衍生物 |
| WO2008020302A2 (en) | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| WO2009025823A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
| US20090062291A1 (en) | 2007-08-22 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
| WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| TW200918519A (en) | 2007-09-19 | 2009-05-01 | Lundbeck & Co As H | Cyanoisoquinoline |
| US20090143361A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| AU2008329775A1 (en) | 2007-11-30 | 2009-06-04 | Biotie Therapies Gmbh | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| EP2227472A1 (en) | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
| US8389567B2 (en) * | 2007-12-12 | 2013-03-05 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2471791B1 (en) * | 2009-08-26 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Fused heterocyclic ring derivative and use thereof |
| US20130203756A1 (en) | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
-
2014
- 2014-02-25 US US14/189,961 patent/US9200005B2/en not_active Expired - Fee Related
- 2014-03-12 UY UY0001035393A patent/UY35393A/es not_active Application Discontinuation
- 2014-03-12 JP JP2015562117A patent/JP2016510786A/ja active Pending
- 2014-03-12 MX MX2015012389A patent/MX2015012389A/es unknown
- 2014-03-12 CN CN201480014146.XA patent/CN105358561A/zh active Pending
- 2014-03-12 EP EP14709320.7A patent/EP2970328B1/en not_active Not-in-force
- 2014-03-12 BR BR112015022094A patent/BR112015022094A2/pt not_active IP Right Cessation
- 2014-03-12 AU AU2014230825A patent/AU2014230825A1/en not_active Abandoned
- 2014-03-12 PE PE2015001893A patent/PE20160040A1/es not_active Application Discontinuation
- 2014-03-12 WO PCT/EP2014/054810 patent/WO2014140086A1/en active Application Filing
- 2014-03-12 KR KR1020157029132A patent/KR20150127724A/ko not_active Application Discontinuation
- 2014-03-12 SG SG11201507380PA patent/SG11201507380PA/en unknown
- 2014-03-12 AR ARP140100879A patent/AR095267A1/es unknown
- 2014-03-12 CA CA2902654A patent/CA2902654A1/en not_active Abandoned
- 2014-03-12 TW TW103108560A patent/TW201441230A/zh unknown
- 2014-03-12 RU RU2015143536A patent/RU2015143536A/ru unknown
-
2015
- 2015-08-16 IL IL240593A patent/IL240593A0/en unknown
- 2015-09-03 DO DO2015000214A patent/DOP2015000214A/es unknown
- 2015-09-04 PH PH12015501962A patent/PH12015501962A1/en unknown
- 2015-09-09 CL CL2015002545A patent/CL2015002545A1/es unknown
- 2015-09-16 CR CR20150496A patent/CR20150496A/es unknown
-
2016
- 2016-06-22 HK HK16107260.0A patent/HK1219273A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR095267A1 (es) | 2015-09-30 |
| CA2902654A1 (en) | 2014-09-18 |
| CR20150496A (es) | 2016-02-19 |
| US9200005B2 (en) | 2015-12-01 |
| IL240593A0 (en) | 2015-09-24 |
| WO2014140086A1 (en) | 2014-09-18 |
| US20140275069A1 (en) | 2014-09-18 |
| BR112015022094A2 (pt) | 2018-06-12 |
| TW201441230A (zh) | 2014-11-01 |
| CN105358561A (zh) | 2016-02-24 |
| HK1219273A1 (zh) | 2017-03-31 |
| PE20160040A1 (es) | 2016-02-11 |
| RU2015143536A (ru) | 2017-04-18 |
| KR20150127724A (ko) | 2015-11-17 |
| CL2015002545A1 (es) | 2016-07-22 |
| AU2014230825A1 (en) | 2015-09-03 |
| SG11201507380PA (en) | 2015-10-29 |
| EP2970328A1 (en) | 2016-01-20 |
| JP2016510786A (ja) | 2016-04-11 |
| EP2970328B1 (en) | 2017-04-26 |
| DOP2015000214A (es) | 2015-12-31 |
| PH12015501962A1 (en) | 2016-01-11 |
| MX2015012389A (es) | 2016-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35393A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| CL2018001624A1 (es) | Antagonistas policíclicos del tlr7/8 y uso de los mismos en el tratamiento de trastornos inmunitarios | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| CO2017003833A2 (es) | Pirimidinonas como inhibidores del factor xia | |
| CR20140223A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| CU24411B1 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos | |
| UY35675A (es) | Derivados sustituidos de quinazolin-4-ona | |
| CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
| CL2013002690A1 (es) | Compuestos derivados de bis(fluoroalquil)-1,4-benzodiazepinona, inhibidores de notch; compuesto cristalino; composicion farmaceutica que los comprende; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| CR20140397A (es) | Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks | |
| SV2017005434A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| SV2018005655A (es) | "derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cancer" | |
| CR20150119A (es) | Compuestos cíclicos éter pirazol-4-il-heterociclil-carboxamida y métodos de utilización | |
| GT201400031A (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
| CU20160183A7 (es) | Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| EA201791802A1 (ru) | СШИТЫЕ ДИГИДРО-4H-ПИРАЗОЛО[5,1-c][1,4]ОКСАЗИНИЛОВЫЕ СОЕДИНЕНИЯ И АНАЛОГИ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ЦНС | |
| MD20160053A2 (ro) | Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative | |
| ECSP16079730A (es) | 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211112 |